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Abstract
Introduction: Little has been written about the use of non-invasive ventilation in the home care of amyotrophic
lateral sclerosis-motor neuron disease patients with end-stage respiratory muscle failure. Nocturnal use of non-
invasive ventilation has been reported to improve daytime blood gases but continuous non-invasive ventilation
dependence has not been studied in this regard. There continues to be great variation by country, economics,
physician interest and experience, local concepts of palliation, hospice requirements, and resources available for
home care. We report a case series of home-based amyotrophic lateral sclerosis-motor neuron disease patients
who refused tracheostomy and advanced non-invasive ventilation to full-setting, while maintaining normal alveolar
ventilation and oxygenation in the course of the disease. Since this topic has been presented in only one center in
the United States and nowhere else, it is appropriate to demonstrate that this can be done in other countries as
well.
Case presentation: We present here the cases of three Caucasian patients (a 51-year-old Caucasian man, a 45-
year-old Caucasian woman and a 57-year-old Caucasian woman) with amyotrophic lateral sclerosis who developed
continuous non-invasive ventilation dependence for 15 to 27 months without major complications and were able
to maintain normal CO2 and pulse oxyhemoglobin saturation despite a non-measurable vital capacity. All patients
were wheelchair-dependent and receiving riluzole 50 mg twice a day. Patient one developed mild-to-moderate
bulbar-innervated muscle weakness. He refused tracheostomy but accepted percutaneous gastrostomy. Patient two
had two lung infections, acute bronchitis and pneumonia, which were treated with antibiotics and cough
assistance at home. Patient three had three chest infections (bronchitis and pneumonias) and asthmatic episodes
treated with antibiotics, bronchodilators and cough assistance at home. All patients had normal speech while
receiving positive pressure; they died suddenly and with normal oxygen saturation.
Conclusions: Although warned that prognosis was poor as vital capacity diminished, our patients survived without
invasive airway tubes and despite non-measurable vital capacity. No patient opted for tracheostomy. Our patients
demonstrate the feasibility of resorting to full-setting non-invasive management to prolong survival, optimizing
wellness and management at home, and the chance to die peacefully.
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Introduction
Amyotrophic lateral sclerosis-motor neuron disease
(ALS-MND) is a rapidly progressive neurological disor-
der in which death is usually due to pulmonary compli-
cations and respiratory failure and survival time is two
and a half to three years from onset of symptoms [1].
At least half of the patients die within 30 months of
onset [2]. Tracheostomy and full-time ventilatory sup-
port are used to prolong survival in some centers; how-
ever, some people finally become cloistered up in those
places (shut-in).
A close monitoring of the patient’s physiological status
and disease progression, and patient counseling on how
to manage the options available are essential [3].
Because of its rapidly progressive nature, ALS-MND is
considered appropriate for palliative care [4,5].
Recommendations about clinical respiratory (sympto-
matic) management are based on ‘current evidence of
best practice,’ which largely comprises a conventionally
accepted clinical opinion [6,7]. Symptomatic palliation is
provided by supplemental oxygen and narcotic/sedative
therapy which exacerbates hypoventilation and may has-
ten death, or by resorting to invasive airway cannulation
and mechanical ventilation. Other options are to use
nocturnal low-span bi-level positive pressure (BiPAP)
ventilation to ameliorate symptoms until, with increas-
ing respiratory muscle weakness this becomes inade-
quate and the patients develop acute respiratory failure
(ARF), are intubated, undergo tracheostomy or die; or
to use palliative drug therapy only until ARF develops
and they die or need a tracheostomy [8,9].
Use of low-span nocturnal-only BiPAP has been
reported to prolong the life of ALS patients by a few
months [10-12]. However, one center has reported an
eight-year survival in patients with ALS through the use
of full-setting, continuous non-invasive ventilation (NIV)
as needed [13] and has also reported similar benefits for
patients with Duchenne muscular dystrophy [14,15].
The diagnosis of ALS was made on the basis of clinical
and electromyographic findings, as defined by revised El
Escorial criteria for diagnosing ALS [16].
We present three cases of home-based patients with
ALS who refused tracheostomy and decided on full-set-
ting NIV, continuous support for 15 to 27 months,
maintaining normal alveolar ventilation and oxygenation
in the process. It is important to point out that these
patients needed NIV continuously at full ventilator set-
tings. Unlike the low spans reported in the literature
[10-12], all three patients required high span inspiratory
positive airway pressure (16 to 20 cm H2O) and an
expiratory positive airway pressure of 4 to 6 cm H2O,
with a back-up rate of about 16 per minute.
Case presentations
Case 1
A 51-year-old Caucasian man with ALS and an 11-
month history of progressive generalized muscle weak-
ness diagnosed five months after onset, was admitted to
our hospital after a two-week history of dyspnea. He
was wheelchair dependent. The patient had tachypnea
and accessory muscle use. Lung auscultation was nor-
mal. Arterial blood gases when breathing ambient air
were pH 7.42, PaO2 60.6 mmHg, PaCO2 60.5 mmHg,
bicarbonate 39.2 mmol/L, and SatO2 91.3%, thus reveal-
ing chronic hypoventilation. Lung function (Vitalograph
2120 spirometer) demonstrated vital capacity (VC) 2.16
L (49% of normal), maximal inspiratory pressure (MIP)
40 cmH2O (38% of normal), maximal expiratory pres-
sure (MEP) of 30 cmH2O (20% of normal), peak flow
(PF) 100, peak cough flow (PCF) 110 L/minute. He
began therapy with NIV via nasal interface during day-
time naps and at night when sleeping. His general con-
dition and dyspnea improved. Arterial blood gas
obtained several days after starting NIV and prior to dis-
charge was pH 7.39, PaO2 88 mmHg, PaCO2 41 mmHg,
bicarbonate 24.8 mmol/L, SatO2 97%. His speech and
video fluoroscopy of swallowing were normal and he
was discharged home with an ALS Functional Rating
Scale-Revised (ALSFRS-R) score of 17 (bulbar domain
9). As disease progressed, he developed mild-to-moder-
ate bulbar-innervated muscle weakness. He accepted
percutaneous gastrostomy. Twenty-six months after
onset of muscle weakness he was 20-hour dependent on
NIV. He died after having used NIV around-the-clock
for 16 months. Clinical and functional follow-up results
are shown in Figure 1.
Case 2
A 45-year-old Caucasian woman with ALS was admitted
to hospital because of dyspnea and morning headache.
She presented with a 22-month history of progressive
muscle weakness, beginning in her left hand. Four
months after onset she was diagnosed with ALS. At pre-
sentation she had severe generalized muscle weakness
and had been wheelchair dependent for the last month.
Three months before, she had had pneumonia. Tachyp-
nea and the use of accessory respiratory muscle were
observed. Arterial blood gases when breathing ambient
air were pH 7.41, PaO2 72 mmHg, PaCO2 50 mmHg,
bicarbonate 31.6 mmol/L, and SatO2 95%; as in the pre-
vious case, chronic hypoventilation was observed. Her
VC was 1.10 L (34% of normal), MIP 20 cmH2O (27%
of normal), MEP 20 cmH2O (22%), PF 85 and PCF 100
L/min. Her speech was normal. Mild dysphagia and
weak cough were observed. She began nasal NIV during
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daytime naps and overnight. Her general condition and
dyspnea improved. Her arterial blood gases normalized
at pH 7.40, PaO2 86 mmHg, PaCO2 40 mmHg, bicarbo-
nate 24.7 mmol/L, and SatO2 97%. She was discharged
home using nasal NIV with an ALSFRS-R score of 16
(bulbar domain 9). She became continuously NIV
dependent within three months. She had two lung infec-
tions, acute bronchitis and pneumonia, which were
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Figure 1 Ratios regarding pulmonary function tests, hours using non-invasive ventilation (NIV) and months of evolution. Panel A -
Vital capacity (VC) in a percentage of the normal values, PaCO2 in mmHg and hours of NIV use. Panel B - Maximal static respiratory pressures at
the mouth: maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) are expressed as a percentage of the normal values. Tests
show a worsening of the pulmonary function, maintaining normocapnia. The NIV duration was increased to full-time NIV for 16 months before
death. During the last few months, VC was non-measurable, and MIP and MEP were zero or non-measurable.
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treated with antibiotics and home cough assistance. Six
months after the last infection she died at home after 15
months of continuous full-setting NIV dependence. For
at least the last five months, her VC was non-
measurable.
Case 3
A 57-year-old Caucasian woman was admitted to hospi-
tal with supine dyspnea. She had a history of bronchial
asthma and a 26-month history of progressive muscle
weakness, beginning in her hands, during an intercur-
rent upper respiratory infection. She was diagnosed with
ALS. Four pulmonary function tests performed over the
past three years were normal. Three months before
coming to us, her VC was 1.98 L (100% of normal). A
week before that, she was unable to walk more than 200
meters because of her fatigue. She was tachypneic and
was using accessory respiratory muscles. Orthopnea and
abdominal paradoxing were present. Arterial blood
gases when breathing ambient air were pH 7.42, PaO2
84 mmHg, PaCO2 38 mmHg, bicarbonate 24.6 mmol/L,
and SatO2 97%. Her lung function measurements
included VC 1.3 L (66% of normal) in the sitting posi-
tion and 0.73 L supine, MIP 30 cmH2O (21% of nor-
mal), MEP 35 cmH2O (39% of normal), PF 120 and PCF
140 L/minute. Her speech was normal but mild dyspha-
gia and weak cough were evident. She began nasal NIV
during daytime naps and overnight and her dyspnea
improved. She was discharged home with an ALSFRS-R
score of 23 (bulbar domain 9). Twenty-three months
after she had been 24-hour dependent on daytime nasal
and nocturnal oronasal NIV, she had three chest infec-
tions (bronchitis and pneumonias) and asthmatic epi-
sodes treated with antibiotics, bronchodilators, and
cough assistance at home. She died after 27 months of
full-time, full-setting NIV at home. For at least the last
eight months before she died, her VC was non-
measurable.
Discussion
There are some clinical aspects in common among all
three patients. They had clinically definite ALS; conse-
quently, they received riluzole 50 mg twice a day [5,6].
After discussing preferences and wishes, all patients
refused tracheostomy. The main indication for NIV was
the patients’ self-reported symptoms (all three of them)
and hypercapnia (the first two patients). All three died
suddenly during the daytime, while talking to their
loved ones. Perhaps they suffered a heart attack. The
key points for the home management of these three
patients were clinical vigilance, serial measurements of
VC and coughing ability, cough assist with ambu bag,
oxygen saturation overnight monitoring and advance
planning.
As with tracheostomy ventilation (TV), full-time NIV
may affect the patient’s safety and comfort but NIV is
invariably preferred by patients who have used both,
and besides, noninvasive management results in fewer
infections and hospitalizations [17-19]. Complications of
both invasive and non-invasive management have been
described [20,21]. The combination of nasal interface
NIV during sleep and mouthpiece NIV when awake
optimizes comfort but most ALS patients eventually
develop too much lip weakness to use mouthpieces and,
thus, must use nasal NIV around the clock. Patients still
invariably prefer this to undergoing tracheostomy [17].
All three patients had been told that NIV would palli-
ate symptoms and ‘buy time’ but that with a decreasing
VC prognosis, this would result in their death. Unlike
using the low BiPAP spans reported in the literature
[10-12] that would buy little time, our patients were
placed on high spans for up to full ventilatory support
and/or respiratory muscle rest. An oximetry feedback
protocol was used at home to screen for atelectasis, air-
way secretions, hypoventilation, and other pulmonary
complications as described [22]. All patients’ dyspnea
and hypoventilation were completely relieved despite
loss of all breathing ability (VC non-measurable) and
they could only talk because of the pressure delivered
by the BiPAP.
Although patients and physicians often consider NIV
more desirable than invasive ventilatory support, with
loss of all VC most clinicians continue to think that tra-
cheostomy is necessary [23]. The cases reported in this
paper support the supposition that this is not so [22].
However, with advancing bulbar-innervated muscle dys-
function such that SpO2 cannot be maintained at 95%
or higher because of continuous saliva aspiration, tra-
cheostomy does become necessary for survival [22]. Tra-
cheostomy, however, can result in 20 years of
institutionalization with loss of all motor abilities and
sometimes communication skills (’shut-in’). As these
cases demonstrate, the use of continuous NIV at set-
tings sufficient for full ventilatory support may maxi-
mize the patient’s chances of returning home and,
eventually, dying there. NIV management, however,
requires good patient and family involvement and realis-
tic expectations [5].
There are now many papers on the importance of
NIV for ALS-MND patients. Cazzolli and Oppenheimer
reported on one patient who used continuous nasal NIV
for two years [11]. Aboussouan et al. noted that those
tolerating NIV, that is, those without severe bulbar-
innervated muscle dysfunction, benefit the most. How-
ever, although bulbar dysfunction can decrease NIV tol-
erance, a trial is not contraindicated [12]. Bach
described prolongation of survival in 36 patients with
ALS by 14 to 17 months and, in some cases, for up to
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eight years by continuous NIV dependence, supplemen-
ted by mechanically assisted coughing, oximetry feed-
back as needed [13], and air stacking [24]. A decrease in
the PF and MEP and in the difference between PCF and
PF was observed, reflecting expiratory muscle weakness
and bulbar impairment [25]. According to the ALSFRS-
R scale, the bulbar involvement when patients were dis-
charged home was mild to moderate. Despite the bulbar
involvement, none of the patients performed a ‘huffing’
maneuver (which is common in patients with bulbar
dysfunction) [26].
We think that survival was very dependent on bulbar
function. With mild to moderate bulbar involvement, it
was possible to maintain NIV with no major support or
difficulties and using occasional cough assist. There
were no major problems with the interfaces. According
to the preferences of patients, they used different types
of masks during the daytime and at night. In one case
(patient two), on the occasion of testing the BiPAP
apparatus with a DC car battery 12 V, the unit stopped
working. It was thus necessary to connect the ambu bag
in order to provide ventilation for three hours until
replacement by the team.
There is no correlation of CO2 levels with a greater
daily use of NIV. Symptomatic hypercapnia at any level
should result in the introduction of NIV but once NIV
has begun, its greater daily use does not correlate with a
requirement for continuous use. Most patients who
require continuous NIV have normal CO2, as also seen
in our three patients. Figure 1 links daytime PaCO2 with
the initiation of NIV and its greater daily use in the day-
time. It can also be seen that PCO2 is normally main-
tained despite the lack of respiratory muscle strength;
thus, VC is non-measurable.
We did not specifically assess the quality of life with
special questionnaires. During the regular follow-up,
patients’ options were reviewed. Patients and their care-
givers were glad to have chosen NIV into the home ven-
tilation setting and would choose it again. Several
studies indicate that NIV improved the symptoms of
hypoventilation, thereby improving the quality of life
and increasing survival of patients with ALS by several
months. TV may increase survival more effectively but
with a greater financial and care burden [10-12,27]. Bul-
bar symptoms partially account for intolerance of NIV,
but should not interdict a trial of non-invasive positive-
pressure ventilation [12]. In the Cazzolli survey, one
hundred percent of the users indicated they were glad
they chose NIV [11]. Of the 25 patients with tracheost-
omy who lived at home, 23 (92%) were satisfied with
their quality of life, while seven (28%) of the other 25
who lived in a Skilled Nursing Care Facility, were not
satisfied with their quality of life, and depression was a
common issue [11].
A recent randomized controlled trial involving 92 ALS
patients shows that NIV improves survival and quality
of life [28]. In patients with severe bulbar impairment,
NIV improves sleep-related symptoms, but is unlikely to
confer a large survival advantage [28,29]. TV can pro-
long survival for many years, can be acceptable for some
patients and caregivers and in these cases can improve
patients’ quality of life, although some patients become
unable to communicate and remain in a shut-in state.
However, home TV is costly and has a significant emo-
tional and social impact on patients and caregivers. The
advantages and drawbacks of TV have been described
[30].
Unlike TV, NIV does not seem to be significantly det-
rimental to caregivers or patients who receive it [28].
Cazzolli shows that unlicensed paid attendants were
employed by some families; and when properly trained,
they provided excellent quality care [11]. Using NIV
when possible is more cost-effective than TV due to
lower costs for both equipment and caregivers. Home
care of patients on long-term mechanical ventilation is
challenging. The financial cost is great, with estimates
ranging up to US$ 200,000/year including 24-hour care
[31,32]. In Argentina, the annual cost of home care for
invasive ventilation, including 24-hour care with skilled
nursing, is about US$ 87,000, while for NIV it is about
US$ 79,000. However, the cost for night nursing of NIV
patients is about US$ 49,000 (case 3), whereas without
nursing it can be reduced to about US$ 33,000 (cases 1
and 2).
Conclusion
Little has been published about the use of NIV in the
care of ALS-MND patients with end-stage respiratory
muscle failure. There continue to be great variations by
country, economics, physician’s interest and experience,
local concepts of palliation, hospice requirements, and
resources available for home care. Our patients, how-
ever, demonstrate the feasibility of non-invasive manage-
ment to prolong survival, optimize wellness and
management at home, and optimize the chances to die
peacefully.
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